Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Other Non-Current Assets: 2023-2025

Historic Other Non-Current Assets for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $5.7 million.

  • Inhibrx Biosciences' Other Non-Current Assets fell 14.51% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 14.51%. This contributed to the annual value of $6.8 million for FY2024, which is 115.90% up from last year.
  • Inhibrx Biosciences' Other Non-Current Assets amounted to $5.7 million in Q3 2025, which was down 15.73% from $6.8 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Other Non-Current Assets peaked at $6.8 million during Q4 2024, and registered a low of $3.2 million during Q4 2023.
  • For the 3-year period, Inhibrx Biosciences' Other Non-Current Assets averaged around $6.1 million, with its median value being $6.7 million (2024).
  • Per our database at Business Quant, Inhibrx Biosciences' Other Non-Current Assets soared by 115.90% in 2024 and then declined by 14.51% in 2025.
  • Inhibrx Biosciences' Other Non-Current Assets (Quarterly) stood at $3.2 million in 2023, then surged by 115.90% to $6.8 million in 2024, then declined by 14.51% to $5.7 million in 2025.
  • Its Other Non-Current Assets was $5.7 million in Q3 2025, compared to $6.8 million in Q2 2025 and $6.8 million in Q1 2025.